Brokers Issue Forecasts for Zoetis Inc.’s FY2017 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Stock analysts at William Blair boosted their FY2017 earnings estimates for shares of Zoetis in a report released on Wednesday. William Blair analyst J. Kreger now forecasts that the company will post earnings of $2.34 per share for the year, up from their previous forecast of $2.31. William Blair also issued estimates for Zoetis’ Q4 2017 earnings at $0.66 EPS, FY2018 earnings at $2.64 EPS, FY2019 earnings at $2.92 EPS and FY2020 earnings at $3.23 EPS.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the consensus estimate of $0.53. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 64.16%. Zoetis’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.49 EPS.

COPYRIGHT VIOLATION NOTICE: This article was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/08/10/brokers-issue-forecasts-for-zoetis-inc-s-fy2017-earnings-nysezts.html.

A number of other analysts also recently issued reports on ZTS. BMO Capital Markets restated a “buy” rating and set a $60.00 price objective on shares of Zoetis in a report on Thursday, May 4th. Jefferies Group LLC raised their price objective on shares of Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, May 9th. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price objective for the company in a report on Wednesday, May 10th. Credit Suisse Group raised their price objective on shares of Zoetis from $61.00 to $67.00 and gave the stock an “outperform” rating in a report on Wednesday, May 24th. Finally, CL King initiated coverage on shares of Zoetis in a report on Friday, May 26th. They set a “buy” rating and a $71.00 price objective for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company. Zoetis has a consensus rating of “Buy” and a consensus target price of $64.78.

Shares of Zoetis (ZTS) opened at 60.81 on Thursday. The company’s 50 day moving average is $62.40 and its 200 day moving average is $57.94. Zoetis has a one year low of $46.86 and a one year high of $63.85. The company has a market cap of $29.85 billion, a P/E ratio of 35.35 and a beta of 1.02.

A number of large investors have recently made changes to their positions in the stock. Guardian Life Insurance Co. of America raised its stake in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares during the last quarter. Sii Investments Inc. WI raised its stake in shares of Zoetis by 0.3% in the first quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock valued at $383,000 after buying an additional 23 shares during the last quarter. Argent Trust Co raised its stake in shares of Zoetis by 0.8% in the first quarter. Argent Trust Co now owns 4,132 shares of the company’s stock valued at $221,000 after buying an additional 32 shares during the last quarter. Ironwood Investment Management LLC raised its stake in shares of Zoetis by 0.7% in the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock valued at $429,000 after buying an additional 48 shares during the last quarter. Finally, CENTRAL TRUST Co raised its stake in shares of Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock valued at $142,000 after buying an additional 49 shares during the last quarter. Institutional investors and hedge funds own 94.51% of the company’s stock.

In other Zoetis news, insider Catherine A. Knupp sold 5,785 shares of Zoetis stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.16, for a total transaction of $348,025.60. Following the completion of the sale, the insider now directly owns 24,415 shares in the company, valued at $1,468,806.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.31% of the company’s stock.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Thursday, June 15th will be given a dividend of $0.105 per share. The ex-dividend date of this dividend is Tuesday, June 13th. This represents a $0.42 annualized dividend and a yield of 0.69%. Zoetis’s payout ratio is presently 23.73%.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply